revive-therapeutics.png
Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
18 sept. 2024 07h00 HE | Revive Therapeutics Ltd.
TORONTO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
revive-therapeutics.png
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections
28 août 2024 07h00 HE | Revive Therapeutics Ltd.
TORONTO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
revive-therapeutics.png
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
02 juil. 2024 13h58 HE | Revive Therapeutics Ltd.
TORONTO, July 02, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
revive-therapeutics.png
Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
12 juin 2024 09h05 HE | Revive Therapeutics Ltd.
TORONTO, June 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
revive-therapeutics.png
Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product
10 juin 2024 07h30 HE | Revive Therapeutics Ltd.
TORONTO, June 10, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
revive-therapeutics.png
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
23 avr. 2024 07h00 HE | Revive Therapeutics Ltd.
TORONTO, April 23, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
revive-therapeutics.png
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
18 avr. 2024 07h00 HE | Revive Therapeutics Ltd.
TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research...
revive-therapeutics.png
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
02 avr. 2024 07h30 HE | Revive Therapeutics Ltd.
TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
revive-therapeutics.png
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
27 mars 2024 09h08 HE | Revive Therapeutics Ltd.
TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
revive-therapeutics.png
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
19 mars 2024 07h00 HE | Revive Therapeutics Ltd.
TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...